Literature DB >> 1350452

Tamoxifen up-regulates c-erbB-2 expression in oestrogen-responsive breast cancer cells in vitro.

S Antoniotti1, P Maggiora, C Dati, M De Bortoli.   

Abstract

Expression of the c-erbB-2 proto-oncogene is inhibited by oestrogens in oestrogen-responsive human breast cancer cells, at both mRNA and protein level. Here we report that, where the regulation of c-erbB-2 is concerned, tamoxifen displays a full anti-oestrogenic activity, enhancing the expression of c-erbB-2 in oestrogen receptor-positive cells cultured with untreated fetal calf serum or reversing the inhibitory effect of added oestrogens. Meanwhile, tamoxifen strongly inhibited cell growth. Tamoxifen was inactive on both c-erbB-2 expression and growth of oestrogen receptor-negative cells. These results may have important implications to explain occasional failure of tamoxifen therapy in oestrogen receptor-positive breast cancers.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1350452     DOI: 10.1016/s0959-8049(05)80045-0

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  11 in total

Review 1.  Transcriptional regulation of type I receptor tyrosine kinases in the mammary gland.

Authors:  N P Bates; H C Hurst
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-04       Impact factor: 2.673

Review 2.  Antiestrogens--tamoxifen, SERMs and beyond.

Authors:  K Dhingra
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

Review 3.  Hormonal regulation of type I receptor tyrosine kinase expression in the mammary gland.

Authors:  M De Bortoli; C Dati
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-04       Impact factor: 2.673

4.  MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo.

Authors:  Y Liu; D el-Ashry; D Chen; I Y Ding; F G Kern
Journal:  Breast Cancer Res Treat       Date:  1995-05       Impact factor: 4.872

5.  Role of neo-adjuvant hormonal therapy in the treatment of breast cancer: a review of clinical trials.

Authors:  Catherine Abrial; Xavier Durando; Marie-Ange Mouret-Reynier; Emilie Thivat; Mathilde Bayet-Robert; Béatrice Nayl; Pascale Dubray; Christophe Pomel; Philippe Chollet; F Penault-Llorca
Journal:  Int J Gen Med       Date:  2009-07-30

Review 6.  Molecular Biology in the Breast Clinics-Current status and future perspectives.

Authors:  Vani Parmar; Nita S Nair; Purvi Thakkar; Garvit Chitkara
Journal:  Indian J Surg Oncol       Date:  2019-08-10

Review 7.  Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases.

Authors:  D F Stern
Journal:  Breast Cancer Res       Date:  2000-03-25       Impact factor: 6.466

8.  Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy.

Authors:  S G Archer; A Eliopoulos; D Spandidos; D Barnes; I O Ellis; R W Blamey; R I Nicholson; J F Robertson
Journal:  Br J Cancer       Date:  1995-11       Impact factor: 7.640

9.  Oestrogen and epidermal growth factor down-regulate erbB-2 oncogene protein expression in breast cancer cells by different mechanisms.

Authors:  S Antoniotti; D Taverna; P Maggiora; M L Sapei; N E Hynes; M De Bortoli
Journal:  Br J Cancer       Date:  1994-12       Impact factor: 7.640

10.  The role of Herceptin in early breast cancer.

Authors:  Ashok Subramanian; Kefah Mokbel
Journal:  Int Semin Surg Oncol       Date:  2008-04-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.